Pfizer Bioprocess Research

Jul 11, 2024 | ascpt.onlinelibrary.wiley.com | Amitava Mitra |Pfizer Bioprocess Research |Mariam Ahmed |Nessy Tania

CONFLICT OF INTEREST The authors declared no competing interests for this work. References 1 et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020). 2, , , & Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet. Med. 23, 2194–2201 (2021). 3 NORD Rare Insights Report.

May 11, 2024 | link.springer.com | Pfizer Bioprocess Research

AbstractThe ICH E17 guidelines (2014–2017) on Multiregional Clinical Trials (MRCT) was a joint effort by the regulators and industry to facilitate simultaneous global drug development and registration through taking a strategic approach for clinical trials.

Jan 2, 2024 | link.springer.com | Pfizer Bioprocess Research

AbstractHigh-throughput experimentation (HTE) has the potential to improve our understanding of organic chemistry by systematically interrogating reactivity across diverse chemical spaces. Notable bottlenecks include few publicly available large-scale datasets and the need for facile interpretation of these data’s hidden chemical insights.